Akums Drugs & Pharma Share Price

Akums Drugs and Pharmaceuticals Limited, with its corporate operations in Delhi, functions as a contract development and manufacturing organization in India. The company provides pharmaceutical products including tablets, capsules, liquid orals, injectables, and topical preparations. Akums Drugs has a substantial reach with manufacturing facilities spread across multiple states in India, including Uttarakhand, Punjab, and Haryana. The company also has a presence in international markets through its subsidiary in Zambia and exports to more than sixty five countries worldwide .

Akums Drugs share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on client order volumes, manufacturing capacity utilization, regulatory compliance success, and the company’s ability to manage raw material costs. Akums Drugs stock price gets influenced by various factors such as earnings reports, regulatory approvals from global bodies, and trends in domestic and international demand for CDMO services. In the longer run, strategies such as capacity expansion, international plant setup, and research and development investments affect the stock market sentiments. All these factors need monitoring to have an idea about the company’s stock price movements.

Akums Drugs live share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Akums Drugs stock price movements helps in observing short term price volatility and shows how a stock moves relative to the broader pharmaceutical index. Furthermore, monitoring Akums Drugs live price helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance and respond to news, quarterly results, or sector trends that may influence the company’s valuation.

Akums Drugs & Pharmaceuticals Limited Fundamentals

A. Company Background

Akums Drugs & Pharmaceuticals Limited was incorporated in 2004 and is engaged in contract development and manufacturing of pharmaceutical and nutraceutical products. The company was founded by Sanjeev Jain and Sandeep Jain. It operates as a contract development and manufacturing organization (CDMO), providing formulation development, manufacturing, and related services to pharmaceutical companies.

Headquartered in New Delhi, the company has established manufacturing facilities in India, particularly in Haridwar, Uttarakhand. It offers a range of dosage forms and supports clients across multiple therapeutic categories. The company’s operations include formulation development, manufacturing, and packaging, catering primarily to domestic pharmaceutical companies and select international markets. Over time, it has expanded its capabilities across formulations and nutraceuticals, with a focus on regulatory compliance and manufacturing scale.

B. Company Product Lines

• Pharmaceutical Formulations

• • Oral solid dosage forms such as tablets and capsules

• • Liquid orals including syrups and suspensions

• • Injectable formulations including sterile products

• Nutraceuticals and Wellness Products

• • Vitamins, minerals, and dietary supplements

• • Products in formats such as tablets, capsules, powders, and gummies

• Dermatology and Cosmetology

• • Topical formulations including creams, ointments, and lotions

• Other Dosage Forms

• • Products such as soft gels, effervescent tablets, and sachets

• Active Pharmaceutical Ingredients (API)

• • Development and manufacturing of select bulk drugs (developing segment)

C. Company Revenue Model

• Contract Development and Manufacturing (CDMO)

• • Revenue from manufacturing pharmaceutical and nutraceutical products for client companies

• Formulation Development Services

• • Income from product development and technology transfer services

• Domestic Business

• • Supply of products to Indian pharmaceutical marketing companies

• Export Sales

• • Revenue from supplying products to international markets

• Value-added Services

• • Packaging, regulatory support, and product customization services

D. Geographic Presence

• Headquarters / Registered Office

• • New Delhi, India

• Manufacturing Facilities

• • Primarily located in India, including Haridwar (Uttarakhand)

• Domestic Presence

• • Serves pharmaceutical companies across India through contract manufacturing

• International Presence

• • Supplies products to select international markets through exports and partnerships

E. Key Milestones

• 2004: Incorporation of Akums Drugs & Pharmaceuticals Limited

• Mid-2000s: Establishment of initial manufacturing facilities in Haridwar

• 2010s: Expansion into multiple dosage forms and nutraceutical segments

• Late 2010s: Scaling up manufacturing capacity and client base

• 2020s: Continued expansion of product portfolio and manufacturing capabilities

• 2024: Listing on Indian stock exchanges through initial public offering

F. Industry Perspective

The pharmaceutical contract development and manufacturing (CDMO) industry is driven by outsourcing trends among pharmaceutical companies, cost efficiencies, and the need for scalable manufacturing. Companies increasingly rely on third-party manufacturers for formulation development and production.

India plays a significant role in this sector due to its manufacturing capabilities, cost competitiveness, and regulatory-compliant facilities. Growth in nutraceuticals and specialty formulations is contributing to diversification within the industry.

The sector is influenced by regulatory requirements, quality standards, and global supply chain dynamics. Demand for pharmaceutical products, including generics and wellness products, continues to support the growth of contract manufacturing service

Akums Drugs Stock Market Presence: Listings & Index Representation

Akums Drugs and Pharmaceuticals Limited is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). Akums Drugs share price is available for trading on the NSE under the symbol AKUMS and on the BSE with the scrip code 544278 . The company’s market presence is primarily within the small-cap segment of the market . Due to its size and sector focus, Akums Drugs stock price is generally tracked by investors interested in the pharmaceutical contract manufacturing industry.

Akums Drugs is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. Akums Drugs share price is a constituent of wider market indices such as the Nifty 500, which tracks a large universe of listed companies across sectors. The company is also included in the Nifty Smallcap 250 and BSE Healthcare indices. In addition, the company is included in multiple BSE indices, including the BSE 500 and broader composite indices which capture companies across large, mid, and small-cap segments.

Akums Drugs Stock Performance and Share Price History

Akums Drugs share price on NSE reflects its status as a contract development and manufacturing organization with a strong focus on formulation development and regulatory compliance in India. Performance gets driven by factors like client order growth, manufacturing capacity utilization, regulatory approval success, and the company’s ability to manage raw material costs effectively. Investors compare Akums Drugs share price today with other CDMOs and pharmaceutical manufacturers to gauge relative performance within the sector.

These underlying factors often appear through real market movements across different periods. Broader sector strength has played a role in supporting Akums Drugs share price. In addition to operational and sector-led factors, corporate actions such as the initial public offering can also have a significant impact on Akums Drugs share price movements. The company completed its IPO in August 2024, listing its shares on the NSE and BSE at a price of six hundred seventy nine rupees per share. This shows how corporate actions can trigger short-term swings, even within a regulated pharmaceutical framework influenced by drug pricing policies and regulatory approvals.

While short-term movements reflect events and announcements, longer-term valuation trends become visible through Akums Drugs share price 52-week high and low, providing context beyond daily or weekly changes . Highs indicate strong client demand and stable margins, while lows align with market corrections or sector volatility . These levels capture the impacts of regulatory policies, competition, and earnings visibility, providing context for the stock’s historical performance.

Akums Drugs stock performance reflects the trading behaviour of a small-cap pharmaceutical company operating within India’s competitive drug manufacturing landscape. The company’s diversified product portfolio across sixty dosage forms and over four thousand commercialized formulations has shaped its Akums Drugs share price history . Over time, the stock has shown fluctuations marked by periods of gains and phases of consolidation following its listing in August 2024 . The company announced a planned investment of approximately two hundred crore rupees in its Zambia-based subsidiary to set up a manufacturing facility and expand business operations in the African market.

Akums Drugs stock performance over time has closely followed India’s pharmaceutical demand and regulatory cycles. For instance, the company’s focus on expanding international presence and its client base including twenty six of the top thirty pharmaceutical companies in India has been viewed favourably . Over shorter investment horizons, the stock has delivered movements that reflect the company’s growth trajectory. The company reported total revenue of over four thousand one hundred crore rupees for the financial year 2024, reflecting its operational scale . The stock reached a 52-week high at a certain level and a 52-week low at a different level, reflecting the volatility inherent in the pharmaceutical CDMO business .

Despite COVID-19 disruptions, Akums Drugs shares showed resilience during its initial listing period. While the broader economy faced challenges with lockdowns and supply chain disruptions, the company’s focus on essential pharmaceutical manufacturing and its diverse client base helped the stock attract investor interest. The company’s manufacturing facilities continued to operate with necessary approvals during lockdowns, as pharmaceuticals were considered an essential service.

Akums Drugs share price has seen decreases due to several recurring reasons. A decline in client orders or a slowdown in the pharmaceutical industry’s outsourcing activity directly impacts revenue and leads to selling pressure. Changes in government policy, such as alterations in drug pricing regulations or changes in manufacturing compliance requirements, can also cause the stock to fall. Furthermore, any increase in operational costs like raw material procurement costs without a matching rise in product revenues squeezes the company’s margins, making the stock less attractive. Periods of economic slowdown that reduce pharmaceutical spending raise concerns about revenue growth, leading to a drop in Akums Drugs share price. The stock is also sensitive to regulatory actions from global bodies like the USFDA or EU-GMP; if any manufacturing facility receives regulatory observations, it can lead to a decrease in Akums Drugs stock price as investors adjust expectations for future profitability . Broader market sell-offs in small-cap stocks also pull the price down, regardless of the company’s individual performance. A decrease in international business revenue from key markets directly hurts the company’s revenue, resulting in a lower valuation for Akums Drugs share price. The company reported a decline in net profit for the second quarter ended September 2025, with profit after tax decreasing by nearly thirty six percent compared to the same quarter in the previous year, reflecting margin pressures and higher operational costs .

Akums Drugs Investor Relevance and Role in Portfolio

Akums Drugs is a holding in pharmaceutical and small-cap portfolios, offering exposure to contract development and manufacturing services, pharmaceutical formulations, and active pharmaceutical ingredients. Inclusion in healthcare indices underscores its importance in India’s pharmaceutical CDMO space. The company’s diversified product portfolio, strong client base including major Indian pharmaceutical companies, and expanding international presence make it a consideration for long-term allocations .

Akums Drugs equity is held by a broad mix of domestic and international institutional investors, reflecting its standing in India’s pharmaceutical sector. Promoter holding remains stable at around seventy five point two six percent, with Akums Master Trust, Sanjeev Jain, and Sandeep Jain as key promoter entities . Prominent mutual fund holders include Smallcap World Fund, Franklin India Smaller Companies Fund, and SBI Healthcare Opportunities Fund . Other institutional investors include Capital Research and Management Company, Franklin Resources, and various domestic asset management companies . This broad investor base with institutional participation underscores the company’s role as a holding in both domestic and global portfolios focused on pharmaceutical manufacturing.

Beyond fundamentals and ownership, Akums Drugs share price is actively monitored by market participants. The stock is available for trading in the futures and options segment on the NSE, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch derivative indicators such as open interest and rollover patterns to gauge sentiment around quarterly results and policy announcements.

Technical indicators such as RSI, MACD, and MFI provide additional insight into short-term momentum shifts in the company’s stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements.

Akums Drugs stock price has exhibited certain volatility patterns. Akums Drugs beta has generally remained at levels reflecting its position as a small-cap pharmaceutical stock with institutional participation and business fundamentals tied to the CDMO industry . Over shorter timeframes, the stock has shown relatively higher sensitivity to market movements, indicating short-term volatility. During the three-month period, this sensitivity appears more balanced, suggesting a closer alignment with broader market trends. Across longer durations, the beta trends in a manner indicating reduced volatility and a weaker correlation with overall market fluctuations. This behaviour is typical for companies in the pharmaceutical CDMO sector with diversified client portfolios. Overall, these variations across different timeframes highlight that while Akums Drugs may experience short-term fluctuations, its longer-term volatility remains characteristic of a small-cap pharmaceutical stock.

Akums Drugs Sectoral Relevance and Peer Positioning

Akums Drugs sector relevance stems from its scale in pharmaceutical contract manufacturing and its strong presence across formulation development, regulatory dossier preparation, and active pharmaceutical ingredient manufacturing . Peer comparisons with companies like Divi’s Laboratories, Torrent Pharmaceuticals, Alkem Laboratories, Mankind Pharma, and Suven Pharma focus on manufacturing capacity, client concentration, regulatory compliance, and geographical presence rather than short-term stock moves . These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of CDMO market growth, pharmaceutical outsourcing trends, and regulatory approvals further highlights Akums Drugs positioning within India’s broader pharmaceutical contract manufacturing market .

Akums Drugs market cap history shows the company’s position within the pharmaceutical CDMO sector. Earlier in its history before the IPO, the company operated as a private entity. The company completed its initial public offering in August 2024, with shares listing on the NSE and BSE at six hundred seventy nine rupees per share . This transition from a private company to a publicly listed entity has been a key factor in how the company’s market capitalization has evolved. The company currently maintains a market capitalization in the small-cap range .

Akums Drugs earnings history demonstrates the impact of its strategic business decisions and external market conditions. In the financial year 2024, the company reported a net profit of nearly one crore rupees, compared to a net profit of nearly ninety eight crore rupees in the financial year 2023, reflecting the cyclical nature of the CDMO business . The company’s revenue showed a CAGR of four percent between financial year 2022 and financial year 2024 . More recently, the company reported a net profit of over forty crore rupees for the quarter ended September 2025, representing a decline from the previous year’s quarter due to margin pressures .

Akums Drugs EPS provides insight into its operational performance and income generation from formulation manufacturing and API sales. Over the years, earnings per share have shown variation in line with the company’s business cycle and industry conditions. The company’s focus on expanding its manufacturing capacity and international presence has influenced the EPS trajectory. Quarterly performance reflects the ongoing earnings from both domestic and international operations, with the CDMO segment contributing significantly to the overall per-share earnings picture . The basic EPS for the quarter ended September 2025 stood at two rupees sixty six paise .

Akums Drugs P/E ratio reflects how investors perceive the company’s earnings relative to its business model. The company’s price-to-earnings ratio has been observed around twenty two, indicating the valuation the market assigns to the company’s earnings . This ratio has moved in response to how investors view the company’s prospects in areas like international expansion and new manufacturing facilities. The company’s focus on setting up a manufacturing facility in Zambia and expanding its production capacity are key factors influencing market sentiment . These changes highlight how market sentiment has evolved alongside the company’s business transformation and expansion strategy.

Summary

Akums Drugs and Pharmaceuticals Limited manufactures pharmaceutical formulations and active pharmaceutical ingredients for domestic and international clients. Akums Drugs share price on the NSE and BSE reflects trading activity within the pharmaceutical contract manufacturing industry. The company has a notable presence in both domestic and international markets. Akums Drugs stock price is influenced by client orders, regulatory approvals, manufacturing capacity utilization, and broader economic factors. The company’s focus on CDMO services and international expansion remains a key aspect of its business profile.